| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5882928 | Clinical Lymphoma Myeloma and Leukemia | 2014 | 33 Pages |
Abstract
Based on these findings, bortezomib retreatment is well tolerated and appears efficacious in relapsed patients. In an era of new and emerging treatment options for relapsed and/or refractory myeloma, these data indicate that bortezomib retreatment might be a highly effective option in previously treated patients.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Kevin B. Knopf, Mei Sheng Duh, Marie-Hélène Lafeuille, Jonathan Gravel, Patrick Lefebvre, Liviu Niculescu, Abbie Ba-Mancini, Esprit Ma, Hongliang Shi, Raymond L. Comenzo,